Streetbeat News

TERN

Terns Pharmaceuticals, Inc.

https://www.ternspharma.com

Industry

Biotechnology

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Open

5.72

Mkt cap

500M

Volume

601K

High

5.98

P/E Ratio

-4.99

52-wk high

11.40

Low

5.64

Div yield

N/A

52-wk low

3.59

Terns Pharmaceuticals has appointed Heather Turner, J.D., to its Board of Directors. Turner brings 25 years of strategic, operational, and legal experience in the biotechnology sector.

Portfolio Pulse from

November 18, 2024 | 9:15 pm

Top Wall Street analysts initiated coverage on several companies, including Alumis Inc., Enliven Therapeutics, Intensity Therapeutics, Terns Pharmaceuticals, and Braze. Notably, Alumis received an Outperform rating with a $25 price target, while Braze was rated Neutral with a $30 target.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 3:37 pm

Oppenheimer has initiated coverage on Terns Pharma with an Outperform rating and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:26 am

Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are now listed as available by the FDA, potentially ending their shortage status. This could impact compounding pharmacies and patients who rely on compounded versions of these drugs.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:52 pm

Several US-listed stocks saw significant gains on Wednesday. Applied Therapeutics surged 72% after the FDA decided an advisory committee meeting was unnecessary. Intuitive Machines rose 52% following a NASA contract award. PowerFleet increased 13% due to an acquisition agreement. Other notable gainers include Bausch + Lomb, Braskem, i-80 Gold, Terns Pharmaceuticals, V.F. Corporation, Gannett, Gyre Therapeutics, Victoria's Secret, and e.l.f. Beauty.

Portfolio Pulse from Avi Kapoor

September 18, 2024 | 1:57 pm

BMO Capital has reiterated its Outperform rating on Terns Pharma and increased the price target from $19 to $26, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:55 pm

Terns Pharmaceuticals' stock is trading lower following the announcement of a $150.1 million public offering, pricing 11,919,048 shares at $10.50 each.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 2:41 pm

Terns Pharmaceuticals has announced an upsized public offering, raising $150.15 million by selling 11,919,048 shares at $10.50 each. The funds will be used for research, clinical trials, and development of key product candidates, as well as for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 6:24 am

Terns Pharmaceuticals shares are experiencing an increase in trading activity following JMP Securities' decision to raise its price target from $15 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:12 pm

Calavo Growers and several other stocks, including Tesla and Oracle, saw significant gains on Tuesday. Calavo Growers reported better-than-expected earnings and increased its dividend, leading to a 12.5% stock price increase. Mission Produce, Avid Bioservices, and Oracle also posted strong earnings, contributing to their stock price rises.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 2:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.